METAP2 and obesity due to melanocortin 4 receptor deficiency: Finally, the development and therapeutic potential of MetAP2 inhibitors are examined, with a particular focus on their mechanisms of action, clinical trial outcomes, and future prospects in treating obesity and T2DM.